Brought to you by Portland Press Ltd.
Published on behalf of the International Federation for Cell Biology
Cancer Cell death Cell cycle Cytoskeleton Exo/endocytosis Differentiation Division Organelles Signalling Stem cells Trafficking
Cell Biology International (2006) 30, 1013–1017 (Printed in Great Britain)
Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro
Robert Hägerkvista, Natalia Makeevaa, Stephen Ellimanb and Nils Welsha*
aDepartment of Medical Cell Biology, Uppsala University, Biomedicum, P.O. Box 571, Husargatan 3, S-75123 Uppsala, Sweden
bDiabetes and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA


Abstract

The tyrosine kinase inhibitor imatinib mesylate (Gleevec) has been demonstrated to protect various cell types from death by inhibition of Abelson tyrosine kinase (c-Abl). The aim of the present study was to establish whether imatinib protects the insulin producing β-cell from the different apoptosis promoting agents in vitro and whether imatinib counteracts streptozotocin-induced diabetes in NMRI mice. We observe that imatinib attenuated the actions of several different death promoting substances. In addition, mice injected with streptozotocin did not develop diabetes when given imatinib. The beneficial effects of imatinib may be related to inhibition of the pro-apoptotic MAP kinase JNK. We conclude that imatinib protects against β-cell death and that this may contribute to the previously reported anti-diabetic actions of imatinib.


Key words: Imatinib, Pancreatic islet, Diabetes, JNK, Apoptosis.

*Corresponding author. Tel.: +46 18 42 12; fax: +46 18 471 40 59.


Received 22 May 2006/14 July 2006; accepted 6 August 2006

doi:10.1016/j.cellbi.2006.08.006


ISSN Print: 1065-6995
ISSN Electronic: 1095-8355
Published by Portland Press Limited on behalf of the International Federation for Cell Biology (IFCB)